Harmonized Lifecycle Management Policy Aims to Drive Drug Quality and Innovation

FDA recently published a final guidance for making post-approval manufacturing changes to drugs and biologics, the culmination of a long-running effort to facilitate improvements in medical product quality through the product life cycle.